Pineal Region Gliomas: A Systematic Review of Clinical Features and Treatment Outcomes

Anticancer Res. 2022 Mar;42(3):1189-1198. doi: 10.21873/anticanres.15585.

Abstract

Background/aim: To review the current literature on pineal region gliomas, summarizing the clinical characteristics and treatment outcomes.

Materials and methods: PubMed, Scopus, and Cochrane databases were used to identify relevant articles. Comprehensive clinical characteristic review and survival analysis were conducted.

Results: Twelve studies describing 81 patients were included. The median age was 39 years (male=54.3%). Fifty patients (61.7%) had obstructive hydrocephalus requiring cerebrospinal fluid diversion with either ventriculoperitoneal shunt (VPS) (40.0%) or endoscopic third ventriculostomy (ETV) (24.0%). Patients who underwent VPS had significant survival benefits compared to ETV (p<0.05). All patients in our review underwent surgery, and gross-total resection (≥98%) was achieved in 34.6%. The supracerebellar infratentorial approach was the most employed surgical approach (62.3%). Chemotherapy was administered in 32.1% of cases, and radiotherapy in 40.7%. The median overall survival (OS) was 12 months, and the overall one-year survival rate was 60%.

Conclusion: This study could not establish a correlation between the extent of tumor resection and positive treatment outcomes. However, among cases with hydrocephalus, patients who underwent VPS placement had better survival as compared to ETV.

Keywords: Pineal region glioma; glioma; pineal region tumors; systematic review.

Publication types

  • Comparative Study
  • Systematic Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Neoplasms / mortality
  • Brain Neoplasms / pathology
  • Brain Neoplasms / surgery*
  • Chemotherapy, Adjuvant
  • Female
  • Glioma / mortality
  • Glioma / pathology
  • Glioma / surgery*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Pineal Gland / pathology
  • Pineal Gland / surgery*
  • Progression-Free Survival
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Time Factors
  • Ventriculoperitoneal Shunt* / adverse effects
  • Ventriculoperitoneal Shunt* / mortality
  • Ventriculostomy* / adverse effects
  • Ventriculostomy* / mortality
  • Young Adult